Another perspective

Anonymous, computer-generated comments from attendees at the Houston Colorectal Cancer Patient Meeting

Section A: Overview of patients participating in the survey

Section B: The initial diagnosis, consultation with a medical oncologist

Section C: Risks and benefits of adjuvant chemotherapy

Section D: Clinical trial participation

Section E: Recovery from chemotherapy, prevention of a second colorectal cancer

Section F: Patient grading of physicians and educational needs for patients

Section G: Bibliography

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of- the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

John L Marshall, MD — Chief, Hematology and Oncology; Director of Developmental Therapeutics and GI Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Consulting Fees: Sanofi Aventis; Fees for Non-CME Services Received Directly from Commercial Interest of Their Agents: Sanofi Aventis; Contracted Research: Sanofi Aventis.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc. AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi- Aventis, who have no influence on the content development of our educational activities.